RNA medicines can target any gene or protein in humans and so can be used to treat diseases that cannot be treated by conventional drugs such as small molecules and biologics.
Our bodies and cells are made up of many different proteins. Diseases occur when genes and proteins inside our bodies malfunction. DNA contains the genetic code needed for cells to make proteins. Various types of RNA, including messenger RNA (mRNA), small interfering RNA (siRNA) and microRNA, work together to control how the genes contained in our DNA are translated into proteins.
Arcturus’ proprietary UNA Oligomer™ and LUNAR™ delivery technologies can be used to make all classes of RNA medicines safe and effective.
NOVA scienceNOW : 8 – RNAi – click to view
May 15, 2017
Ernst & Young Selected Arcturus as the Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego
April 29, 2017
Arcturus Therapeutics to Present at the TIDES--Oligonucleotides and Peptide Therapeutics, on Unlocked Nucleomonomer Agent (UNA) Oligomer System, Challenges and Opportunities
April 10, 2017
Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego